A
Abatacept, 48, 205, 298–299
Achilles tendon, 114
calcific tendinopathy, 212
insertion in calcaneus, 193, 194
Acitretin, psoriasis
laboratory testing, 223
topical therapy, 262
ACPA. See Anti-citrullinated protein antibodies (ACPA)
Acute guttata psoriasis, 132, 135
Adalimumab
psoriasis, 283
psoriatic arthritis, 298
Alopecia areata, 145
AM. See Arthritis mutilans (AM)
American College of Rheumatology (ACR), 10
Angiogenesis, 54, 74, 77, 121
Animal models, 103–104, 108
for biomedical research, 104
psoriasis
gain and loss of function, 106
humanized models, 106
induced models of, 106
spontaneous model, 105–106
psoriatic arthritis
bone remodelling, 118–121
disease models, 104
induced models of, 107–108
spontaneous models, 107
transgenic approaches, 107
translational challenges, 104–105
Ankylosing spondylitis (AS), 94
clinical features, 151–152
X-rays, 180–181
Ankylosing Spondylitis ASsessment (ASAS) group, 8
Ankylosis
models of, 107
on MRI, 200
plain radiograph, 179
psoriatic arthritis, 300
Anti-citrullinated protein antibodies (ACPA), 148, 229–230
Antigen-presenting cells (APCs), 47
Anti-TNF therapy, PsA
baseline laboratory tests, 232
bone remodelling, 116
MMP-3, 234–235
Apremilast, 48
PsA, 272–273
psoriasis, 262–263
Arthritis mutilans (AM)
radiographic assessment, 176–177
with telescopic finger, 151
Arthrosonography, 150, 157
AS. See Ankylosing spondylitis (AS)
Assessment of SpondyloArthritis international Society
(ASAS) classification
axial SpA, 200
psoriatic arthritis, 148–149
Auspitz phenomenon, 131, 135
Axial disease
assessment, 11
non-symptomatic, 24
radiographic assessment, 177–180
ultrasound, 194
Axial PsA, MRI
in clinical trials, 206
description, 200, 202–204
Axial spondyloarthritis (AxSpA), 111, 121
B
Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI), 156
Berlin-activity method, 206
Beta-adrenergic blockers, 130
Biological disease modifying anti rheumatic drugs
(bDMARDS), 40
Biologic therapy
psoriasis
efficacy, head-to-head study, 285–286
extracutaneous effects, 288–289
IL-12/-23 antagonists, 284
IL-17 antagonists, 284–285
immunogenicity, 288
international travelers, 290–291
patients with viral hepatitis, 290
in pregnancy, 289–290
Biologic therapy (cont.)
risk factors, 286–288
screening patients, 289
TNF-α antagonists, 282–284
treatment combinations, 286
psoriatic arthritis
B lymphocyte inhibitors, 299
costimulatory blockade agent, 298–299
development costs, 305
in early PsA patients, 304
IL-6 inhibitors, 299
IL-12-23 inhibitors, 301–302
IL-17 inhibitors, 302–304
IL-23 inhibitors, 304
immunogenicity avoidance, 304–305
TH17 cell differentiation, 299–301
TNFα inhibitors, 296–298
TNFi safety, 298
treat-to-target strategies, 305
B lymphocytes, 56, 299
BMO. See Bone marrow oedema (BMO)
B mode/grey scale ultrasound, 190–192, 196
BMP pathway, bone remodelling, 116–117
Bone erosions
on MRI, 200
three-dimensional US, 210
ultrasound, 192
Bone formation
BMP pathway, 116–117
lessons from animal models, 118–120
mechanical stress, 117–118
in psoriatic arthritis, 79
spinal arthritis, 112
Wnt signaling pathway, 116
Bone homeostasis, 115–117, 120–121
Bone marrow oedema (BMO), 200–202, 205
Bone proliferations, 175, 176, 178, 180, 200
Bone remodelling, PsA, 111
animal models, 118–121
anti-TNF therapy, 116
BMP pathway, 116–117
clinical spectrum of, 112–113
dactylitis, 114
DKK-1, 116, 118
enthesitis, 114
GWAS, 120–121
mechanical stress, 117–118
MRI maging, 114
nail disease, 113–114
NSAIDs, 120, 121, 123
radiographic changes of, 112–113
synovitis, 114–115
TNF-brake hypothesis, 118
treatment effects on, 121–122
Wnt Signaling Pathway, 116
Broadband UVB (BBUVB), 260
Brodalumab, 48
psoriasis, 285
psoriatic arthritis, 303–304
C
Calcaneus Achilles tendon in, 179, 193, 194
Candidate gene studies, PsA
HLA region, 94
non-HLA region, 95–96
CARD14, 88–89
Cardiovascular disease (CVD)
comorbidities in psoriatic arthritis, 35
epidemiology, 35
IMT assessment, 213
CASPAR criteria. See Classification criteria for the diagnosis of Psoriatic Arthritis (CASPAR) criteria
CCAAT-enhancer-binding protein (C/EBP), 98
Cellular composition, 62–63
Certolizumab, 48
psoriasis, 284
psoriatic arthritis, 298
Chronic plaque-type psoriasis, 131, 135
Classification criteria for the diagnosis of Psoriatic Arthritis (CASPAR) criteria, 7, 8, 28, 149
evolution of, 24–26
nature of, 17–18
performance of, 22, 23
for PsA, 18–22
for psoriasis, 18
for SpA, 23–24
Clazakizumab, 299
Copy number variants (CNVs), 94
Corticosteroids, psoriasis, 254, 257
CVD. See Cardiovascular disease (CVD)
Cyclosporine, psoriasis
laboratory testing, 223
topical therapy, 259–260
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)-immunoglobulin, 46
D
Dactylitis, 40, 156
clinical features, 150–151
features of, 25
MRI studies of, 114
ultrasound, 194
Dendritic cells (DCs), 56–57, 68–69, 74
Dermatology Life Quality Index (DLQI), 136, 137
Discovertebral lesions, 179
Distal arthritis, 113–114
E
Elastosonography (ES), 212
Enthesiopathy, 153
Enthesis organ, 114
Enthesitis, 55, 113, 114, 194
clinical features, 151, 152
features of, 25
radiographic features, 179
in spondyloarthropathies, 69
whole-body MRI, 202–204
Enthesopathy, 19, 192, 194
Erosive osteoarthritis (EOA), 174, 181–182
Erythematous plaque, 140
Erythroderma, 134
Erythrodermic psoriasis, 134–135
ES. See Elastosonography (ES)
Etanercept
psoriasis, 283
psoriatic arthritis, 297
European League Against Rheumatism (EULAR), 8, 10
European Society of Musculoskeletal Radiology, 193
European Spondyloarthropathy Study Group (ESSG), 19

F
Feet, radiographs, 175–176, 179
FI. See Fusion imaging (FI)
Five Targets Power Doppler for Psoriatic Disease (STPD), 167
FK506, 263–264
Framingham risk factor score (FRS), 35
Fusion imaging (FI), 213–215

G
γδ T cells, 66–67
Generalized pustular psoriasis, 133
Genetics of psoriasis
epidemiology, 84
HLA-Cw6, 84–85
IL4/IL5/IL13, 86
IL12B, 86
IL23A, 86
IL23R, 86
PSORS1, 84–85
PSORS2-9, 86
RAD50, 86
TNFAIP3, 87
TNIP1, 87
Genome-wide association studies (GWAS)
bone remodelling, 120–121
and epidemiologic genetic studies, 89
psoriatic arthritis, 96–98
German Psoriasis Arthritis Diagnostic (GEPARD)
Questionnaire, 155
Global Severity Score (GSS), scalp psoriasis, 140
Glucagonoma syndrome, 135
Golimumab, 48
psoriasis, 283–284
psoriatic arthritis, 298
Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, 245–246
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), 10, 182, 244–246
Guselkumab, 48, 304
Guttate psoriasis, 132, 133, 135
GWAS. See Genome-wide association studies (GWAS)

H
Hands, radiographs, 174–178
Health Assessment Questionnaire (HAQ), 4
HLA-Cw6, 84–85, 86
Human leukocyte antigen (HLA) region, psoriatic arthritis, 94
Hydroxyurea, 264
Hypertrophy, 54

I
IBD. See Inflammatory bowel disease (IBD)
Idiopathic osteoarthritis, 153
IL4, 86
IL5, 86
IL-12, 77–79
IL12B, 86
IL13, 86
IL-17, 64–65, 77–79
IL-23, 77–79
IL-23A, 86
IL23R, 86
IL-33, 47
IL-36RN, 88
Immunopathology
nails, 48–50
skin, 45–48
Indo-cyanine-green (ICG), psoriatic arthritis, 157
Inflammatory bowel disease (IBD), 152–153
Infliximab
psoriasis, 282–283
psoriatic arthritis, 298
Innate immune system, 65–66
dendritic cells, 68–69
γδ T cells, 66–67
innate lymphoid cells, 67–68
MAIT cells, 68
NK cells, 67
spondyloarthropathies, 69
Innate lymphoid cells (ILC), 67–68
Interferon alpha, 46
Interleukin-6 (IL-6), PsA, 235
Interleukin 17A (IL-17A)
psoriasis, 287–288
psoriatic arthritis, 299–301
International League Against Rheumatism (ILAR), 8
International Psoriasis and Arthritis Research Team (IPART), 12
Intima-media thickness (IMT) assessment, 213, 214
Intranasal influenza vaccine, 289
Inverse psoriasis, 132, 135
Ivory phalanx, 175
Ixekizumab, 48
psoriasis, 285
psoriatic arthritis, 303

J
Janus kinase (JAK) inhibitors, 48, 273
Juxta articular bone involvement, 55–56
**K**  
Keratinocytes, 62  
Killer-cell immunoglobulin-like receptors (KIR), 95  
Koebner phenomenon, 130

**L**  
Laboratory testing  
PsA  
anti-citrullinated cyclical peptide antibodies, 229–230  
anti-TNF therapy, 232  
avtoantibody tests, 230  
bionuclears, 232  
cellular blood biomarkers, 235  
clinical phenotypes, 236–237  
C-reactive protein, 227–228  
disease severity, 237  
DMARD therapy, 230–232  
erthrocyte sedimentation rate, 227–228  
genetic associations, 236  
haematological parameters, 228  
hyperuricemia, 230  
interleukin-6, 235  
plasma viscosity, 228  
rheumatoid factor, 229  
synovial tissue biopsy, 235  
synovial fluid biomarkers, 229  
synovial fluid, 228  
synovial tissue biopsies, 235  
urine biomarkers, 235–236  
psoriasis  
acitretin, 223  
biologic therapy, 223–225  
cyclosporine, 223  
differential diagnosis, 222  
HLA-Cw6 allele, 225  
methotrexate, 222  
phototherapy, 222  
topical therapies, 222  
Lattice System Physicians’ Global assessment tool (LS-PGA), 136–137  
Leeds Dactylitis Instrument, 156  
Leeds Enthesitis Index (LEI), 156  
Leflunomide, PsA  
DMARDs, 271  
laboratory tests, 231–232  
Leukonychia, 144–145  
Lymphocyte function-associated antigen 3 (LFA-3), 48  
Lymphocytes  
B lymphocytes, 56, 299  
T lymphocytes, 56

**M**  
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), 156  
Macrophages, 57, 63, 66, 69, 300  
Magnetic resonance imaging (MRI)  
psoriasis, 210, 213–214  
psoriatic arthritis, 157, 174, 199, 210  
Berlin-activity method, 206  
Canada-Denmark system, 206  
in clinical trials, 206  
diagnosis, 201–202  
monitoring, 202–206  
prognostication, 202  
qualitative methods, 204  
quantitative methods, 204  
semiquantitative methods, 204–206  
SPARC scoring system, 206  
technique and findings, 200–202  
Major Histocompatibility Complex (MHC), 48  
psoriatic arthritis, 94  
susceptibility loci within, 85–86  
MASES. See Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)  
Medical Outcome Survey Short Form 36 (SF-36), 4  
Metacarpophalangeal (MCP) joints  
longitudinal dorsal scan at, 192  
longitudinal lateral scans, 193, 195  
MRI of, 201  
three-dimensional US, 211  
transverse lateral scans, 193, 195  
Methotrexate (MTX)  
PsA  
DMARDs, 268, 271  
laboratory tests, 230–231  
psoriasis  
laboratory testing, 222  
topical therapy, 257–259  
MHC. See Major Histocompatibility Complex (MHC)  
Modified NAPSI (mNAPSI), 145  
Modified Sharp score (MSS), 182  
Modified Stoke’s AS spine score (mSASSS), 121  
Monogenic disorders, 104  
MSK symptom, 24, 25  
Mucosa-associated invariant T (MAIT) cells, 68  
Musculoskeletal ultrasound, 190  
Mycosis fungoides, 135

**N**  
Nail Area Severity (NAS) system, 145  
Nail bed disease, 144  
Nail matrix disease, 144  
Nail psoriasis  
clinical assessment, 144–145  
clinical features, 144  
clinical signs, 143  
differential diagnosis, 145  
epidemiological studies, 143  
modified NAPSI, 145  
NAPSI, 145  
NAS system, 145  
N-NAIL tool, 145  
PASI, 144  
Nail Psoriasis Severity Index (NAPSI), 145  
Nails
assessment  
grayscale image of, 165  
ultrasound, 194–195  
disease, 113–114  
healthy, 164  
immunopathology of, 48–50  
Narrowband ultraviolet B (NBUVB), 260, 261  
NAS system. See Nail Area Severity (NAS) system  
National Health and Nutrition Examination Survey (NHANES), 34  
Natural killer (NK) cells, 67, 84  
Nijmegen-Nail psoriasis Activity Index tooL (N-NAIL), 145  
Non-HLA region, psoriatic arthritis, 95–96  
Non-steroidal anti-inflammatory drugs (NSAIDs), PsA, 120, 121, 123  
erythematous, 140  
psoriatic, 164–168  
Plaque-type psoriasis  
clinical manifestation, 130–135  
differential diagnosis, 135  
Koebner phenomenon, 130  
types, 130  
Plasmacytoid dendritic cells, 46  
Polyarthritis, 150  
Polymorphonuclear leukocytes (PMNs), 63  
Power Doppler (PD), 164, 190, 191  
Pre-osteoclasts, 57–58  
Proinflammatory cytokines release, 47  
PsA. See Psoriatic arthritis (PsA)  
PsAMRIS. See Psoriatic Arthritis Magnetic Resonance Image Score (PsAMRIS)  
PsO. See Psoriasis (PsO)  
Psoralen, 260  
Psoralen with UV A (PUVA), 261–262  
Psoriasis (PsO)  
animal models  
gain and loss of function, 106  
humanized models, 106  
induced models of, 106  
spontaneous model, 105–106  
T cells, 106  
CASPAR criteria for, 18  
cellular composition of, 62–63  
clinical manifestation, 130–135  
cytokine signaling in, 47  
diagnosis of, 164  
differential diagnosis, 135  
DLQI, 136, 137  
endogenous factors, 130  
generalized pustular psoriasis, 133  
genetics of  
epidemiology, 84  
HLA-Cw6, 84–85  
IL4/IL5/IL13, 86  
IL12B, 86  
IL23A, 86  
IL23R, 86  
PSORS1, 84–85  
PSORS2-9, 86  
RADS50, 86  
TNFAIP3, 87  
TNIP1, 87  
inflammatory process in, 54  
LS-PGA, 136–137  
magnetic resonance imaging, 210, 213–214  
missing heritability of, 87–88  
PASI, 135–137, 140, 144  
PBI, 137  
PGA, 136  
prevalence of, 34–35  
psoriatic arthritis prevalence in, 29–32  
ultrasound, 190–196, 210, 213–214  
Psoriasis Area and Severity Index (PASI), 135–137, 140, 144, 164  
Psoriasis Epidemiology Screening Tool (PEST), 155  

O  
OCPs. See Osteoclast precursors (OCPs)  
Octamer transcription factor-3 (OTF3), 85  
Oligoarthritis, 149–150  
Onycholysis, 144–145  
Onychomycosis, 145  
OPG. See Osteoprotegerin (OPG)  
OSCAR. See Osteoclast-associated receptor (OSCAR)  
Osteitis  
differential diagnosis, 153  
symptoms, 153  
Osteoblast, 115, 116, 120  
Osteoclast-associated receptor (OSCAR), 115  
Osteoclast precursors (OCPs), 57–58, 115  
Osteoclasts, 57–58, 115, 121  
Osteoprotegerin (OPG), 115  
Outcomes Measures in Rheumatology (OMERACT) Group, 11–12  
MRI, 204  
ultrasound, 192, 194  
P  
Palmpoplantar pustular psoriasis, 133–134  
PASI. See Psoriasis Area and Severity Index (PASI)  
Patient Benefit Index (PBI), 137  
PD. See Power Doppler (PD)  
Peripheral arthritis, 193  
Peripheral PsA, MRI  
in clinical trials, 204–206  
diagnosis, 201–202  
monitoring, 202  
prognostication, 202  
whole-body MRI, 202–204  
PEST. See Psoriasis Epidemiology Screening Tool (PEST)  
PGA. See Physician Global Assessment (PGA)  
Pharmacogenetics, psoriatic arthritis, 98–99  
Phototherapy, 254, 260, 262  
Physician Global Assessment (PGA), 136  
Plaques, 130
Psoriasis Scalp Severity Index (PSSI), 140
Psoriatic arthritis (PsA), 93
animal models
  bone remodelling, 118–121
disease, 104
induced models, 107–108
joint damage in, 107
spontaneous models, 107
transgenic approaches, 107
translational challenges, 104–105
ASAS classification, 148–149
bone formation, 79
candidate gene studies
  HLA region, 94
  non-HLA region, 95–96
case–control association studies, 95
CASPAR criteria, 18–22, 149
cellular composition of, 62–63
characteristics, 54
classification, 148–149
clinical course of, 40
clinical features, 149–153
collaborative working
  benefits, 244
dermatology and rheumatology clinics, 245
copy number variants, 94
criteria for, 28
CVD comorbidities in, 35
cytokine signaling in, 47
dendritic cells, 56–57
diagnosis, 32
differential diagnosis, 153–154
disease activity, 39
eye disease, 148
early intervention, 247–248
enthesitis, 55
epidemiology, 148
EULAR guidelines, 244, 247
familial recurrence risk, 29
features of, 25
gene-environment interactions, 94, 99
gene-gene interactions, 94
genome-wide association studies, 96–98
GEPRAD questionnaire, 155
GRAPPA treatment recommendations, 244
high-resolution transducers, 215
historical perspectives on, 3–5
incidence, 32–34
indo-cyanine-green, 157
inflammatory process in, 54
joint damage in, 107
juxta articular bone involvement, 55–56
KIR, 95
lymphocytes, 56
macrophages, 57
male-to-female ratio, 28–29
management, 5
MRI, 157, 199–206, 210, 213–214
natural history of, 39–41
osteitis, 55–56
osteoclasts, 57–58
pathologic bone resorption in, 115–116
PDUS, 166, 167
pharmacogenetics and, 98–99
physical function, 40
pre-osteoclasts, 57–58
prevalence, 163
  in general population, 28–30
  in psoriasis patients, 29–32
questionnaires for, 154–155
radiography, 112–113, 156–157
in Spanish cohorts, 95
step up vs. step down therapy, 246
symptoms, 148
synovitis, 54–55
szintigraphy, 157
TICOPA study, 249
TICORA study, 248–249
tools for early diagnosis, 154–155
treatment withdrawal/reduction, 249–250
ultrasound, 190–196, 210, 213–214
Psoriatic Arthritis Magnetic Resonance Image Score (PsAMRIS), 204–206
Psoriatic Arthritis Screening and Evaluation (PASE)-Questionnaire, 155
Psoriatic disease, 73
  IL-12/IL-23/IL-17, 77–79
  immunopathogenesis, 74–79
  T cells in, 74–75
Psoriatic nail, 215
Psoriatic nail dystrophy, 48
Psoriatic onychopathy, 166
Psoriatic plaques, 167
greyscale image, 165
ultrasound, 164–166
video-capillaroscopy, 168
Psoriatic skin, 215
PSORS1, 84–85
PSORS2-9, 86
PSSI. See Psoriasis Scalp Severity Index (PSSI)
Pustular psoriasis
  CARD14, 88–89
differential diagnosis, 134
generalized, 133
  IL-36RN, 88
  palmoplantar, 133–134
  phenotypes, 88
Q
  Quality Intima-Media Thickness (QIMT), 213
R
  RA. See Rheumatoid arthritis (RA)
  RAD50, 86
Radiographs
  PsA, 112–113
  psoriatic arthritis, 173
Tight Control of Psoriatic Arthritis (TICOPA) study, 249
Tight Control of RA (TICORA) study, 248–249
Tildrakizumab, 48, 304
Tinea capitis, non-inflammatory, 140
T lymphocytes, 56
TNF. See Tumor necrosis factor (TNF)
TNF alpha inhibitors, 46

psoriasis
classification and efficacy, 282
incidence, 287
risk factors, 286–287
side effects, 287
treatment of, 287
psoriatic arthritis, 296, 297
TNF-induced protein 3 (TNFAIP3), 87, 97–98

Tofacitinib, 48
DMARDs, PsA, 273–274
psoriasis, 263

Toll-like receptors, 46

Topical therapies, psoriasis
acitretin, 262
apremilast, 262–263
corticosteroids, 254, 257
cyclosporine, 259–260
limitations, 254
methotrexate, 257–259
NBUVB, 261
phototherapy, 260
PUVA, 261–262
tazarotene, 257
tofacitinib, 263
ultraviolet B, 260–261
vitamin D analogs, 257

Toronto PsA Screening (ToPAS) Questionnaire, 154
Total Severity Scale (TSS), scalp psoriasis, 140

Traditional disease-modifying antirheumatic drugs (DMARD)
future considerations, 276
JAK inhibitors, 273
leflunomide, 231–232, 271
methotrexate, 230–231, 268, 271
observational studies, 269–270
phosphodiesterase four inhibitor, 272–273
physical therapy, 274–275
randomized control trials, 269–270
rehabilitative therapy, 274–275
sulfasalazine, 231, 271–272
surgical management, 275–276
with TNFI, 272
tofacitinib, 273–274

Transaminitis, 258

Tumor necrosis factor (TNF), 75–77, 107

T1-weighted sequences, psoriatic arthritis, 200

U
Ultrasound (US), 164

advantages, 190
B mode/grey scale, 190–192, 196
treatment, 196
bone erosion, 192
clinical finding, 194
tenosynovitis, 192
treatment of, 196
healthy nail, 164
healthy skin, 164

IMT assessment, 213
musculoskeletal, 190

OMERACT Group, 192, 194
psoriasis, 210, 213–214
psoriatic arthritis, 210
psoriatic onychopathy, 166
psoriatic plaques, 164–166
in psoriatic skin/nail, 166
research agenda, 196
rheumatology, 190–191

skin assessment, 194–195

synovial fluid, 192

synovial hypertrophy, 192

therapeutic monitoring, 166–167, 196

three-dimensional, 210–212

usefulness, 193

vs. VCP, 169–170

Ultraviolet B (UVB), 260–261

Ustekinumab, 48
psoriasis, 284
psoriatic arthritis, 301–302

Uveitis, 40

V
Vascular endothelial growth factor (VEGF), 46

Videoangiography (VCP), 164
psoriatic plaque, 168
in skin psoriasis, 167–168
differential diagnosis, 168–169
treatment monitoring, 169

US vs., 169–170

Vitamin D analogs, 257, 261

W
Whole-body MRI, PsA, 202–204
Wnt Signaling Pathway, PsA, 116

X
X-rays, psoriatic arthritis
differential diagnosis, 180–182
prognosis, 182

Z
Zoster vaccine, 289